AKTS
Aktis Oncology, Inc.Company Information
- Company Name
- Aktis Oncology, Inc.
- CIK
- CIK0002035832
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- AKTS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- AKTS
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-01-12
- Last sale
- 2026-09-23
- Shares purchased (TTM)
- 6,350,646
- Shares sold (TTM)
- 120,421
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 31,502,723
- Shares outstanding
- 55,300,107
- Ownership
- 56.97%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 13.70%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|
| Series Seed Redeemable Convertible Preferred Stock | 0 | 0 | ||||||
| Series A Redeemable Convertible Preferred Stock | 0 | 0 | ||||||
| Series B Redeemable Convertible Preferred Stock | 0 | 0 | ||||||
| Partner Redeemable Convertible Preferred Stock | 0 | 0 | ||||||
| Common Stock | -53 | 53 | ||||||
| Common Class A | 54 | 0 | ||||||
Assets Current | ||||||||
| Cash And Cash Equivalents At Carrying Value | 82 | 372 | ||||||
| Marketable Securities | 435 | 167 | ||||||
| Prepaid Expense And Other Assets Current | 7 | 5 | ||||||
| Assets Current | 525 | 544 | ||||||
| Property Plant And Equipment Net | 16 | 15 | ||||||
| Operating Lease Right Of Use Asset | 12 | 13 | ||||||
| Restricted Cash Equivalents Noncurrent | 1 | 1 | ||||||
| Other Assets | 4 | 4 | ||||||
| Assets | 558 | 577 | ||||||
Liabilities Current | ||||||||
| Accounts Payable Current | 3 | 1 | ||||||
| Accrued Liabilities Current | 11 | 6 | ||||||
| Deferred Revenue Current | 17 | 19 | ||||||
| Operating Lease Liability Current | 1 | 1 | ||||||
| Liabilities Current | 32 | 28 | ||||||
| Deferred Revenue Noncurrent | 31 | 33 | ||||||
| Operating Lease Liability Noncurrent | 10 | 10 | ||||||
| Liabilities | 73 | 71 | ||||||
Stockholders Equity | ||||||||
| Additional Paid In Capital Common Stock | 685 | 681 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -199 | -175 | ||||||
| Stockholders Equity | 485 | 506 | ||||||
| Liabilities And Stockholders Equity | 558 | 577 | ||||||
| Common Stock No Par Value | 0 | 0 | ||||||
| Common Stock Shares Authorized | 480 | 480 | ||||||
| Common Stock Shares Issued | 53 | 53 | ||||||
| Shares Outstanding | 53 | 53 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAktis Oncology, Inc. (AKTS) — SEC Financial Statements & Analysis
Aktis Oncology, Inc. (AKTS) is a pharmaceutical preparations company, incorporated in DE. Aktis Oncology, Inc. trades on Nasdaq as: AKTS. Aktis Oncology, Inc. (AKTS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Aktis Oncology, Inc. carries a market cap of $1.78B, a P/B ratio of 3.68x, and an enterprise value of $1.70B. On the balance sheet, it maintains a current ratio of 16.33x, a quick ratio of 16.10x, working capital of $492.41M, a debt-to-equity ratio of 0.15x, a debt ratio of 0.13, and net debt of $-83.64M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.78B
- P/B TTM
- 3.68x
- Debt To Equity
- 0.15x
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Aktis Oncology, Inc. in?
Aktis Oncology, Inc. (AKTS) operates in the Pharmaceutical Preparations industry.
What exchange does AKTS trade on?
Aktis Oncology, Inc. (AKTS) trades on the Nasdaq.
Where is Aktis Oncology, Inc. incorporated?
Aktis Oncology, Inc. is incorporated in DE.
When was Aktis Oncology, Inc. (AKTS)'s most recent SEC filing?
Aktis Oncology, Inc. (AKTS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is AKTS's market cap?
Aktis Oncology, Inc. (AKTS) has a market capitalization of $1.78B as of 2026-06-30.